Risk of Venous Thromboembolism in Patients With Stage III and IV Non-Small-Cell Lung Cancer: Nationwide Descriptive Cohort Study.
Anne Gulbech OrdingThomas Decker ChristensenFlemming SkjøthSimon NobleAnette Arbjerg HøjenAmalie Lambert MørkvedTorben Bjerregaard LarsenRene Horsleben PetersenPeter MeldgaardErik JakobsenMette SøgaardPublished in: Clinical lung cancer (2024)
VTE risks vary substantially according to cancer treatments and cancer stages. The highest risk was observed in the initial 6 months of therapy initiation. These insights emphasize the need for tailored risk assessment and vigilance in managing VTE complications in patients with NSCLC. Further research is needed to optimize individual thromboprophylaxis strategies for patients with unresectable and metastatic NSCLC.
Keyphrases
- venous thromboembolism
- small cell lung cancer
- direct oral anticoagulants
- papillary thyroid
- risk assessment
- squamous cell
- squamous cell carcinoma
- human health
- cross sectional
- advanced non small cell lung cancer
- heavy metals
- childhood cancer
- lymph node metastasis
- mesenchymal stem cells
- young adults
- atrial fibrillation
- smoking cessation
- liver metastases
- epidermal growth factor receptor
- tyrosine kinase
- cell therapy